Pacesetter begins trials of Angeion's Aegis:
This article was originally published in Clinica
Executive Summary
Pacesetter has begun clinical trials of Angeion's Aegis implantable cardioverter defibrillator (ICD). The first implant was performed at Ohio State University Medical Center in the US. The cardiac rhythm subsidiary of St Jude Medical is conducting the trials at sites in the US and Europe and will market the product for Angeion following regulatory approval. Minneapolis-based Angeion is continuing trials in the US of its Sentinel 2000 ICD system which already has European approval. Angeion is also developing radio frequency and laser catheter ablation systems.